Qiming Leads $29M Round In Chinese Antibody Drug Developer Sino Biological

For Digital Subscribers Only

China-focused venture capital firm Qiming Venture Partners has led a RMB200 million (US$29 million) series A round in Sino Biological Inc., a Beijing-based recombinant protein and antibody developer, according to a company announcement.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

RELATED NEWS



LEAVE A REPLY